Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a report published on Monday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price for the company.

Lipocine Trading Down 9.0 %

Shares of LPCN opened at $4.74 on Monday. The firm has a market cap of $25.35 million, a P/E ratio of -6.24 and a beta of 1.24. The stock’s 50 day moving average is $5.17 and its two-hundred day moving average is $5.49. Lipocine has a 12 month low of $2.44 and a 12 month high of $11.79.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. Equities research analysts forecast that Lipocine will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new stake in Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.